ClinicalTrials.gg

Program

tilrekimig

Also written as “PF-07275315”, “Tilrekimig” and “PF-07275315 dose 1”.

In Pfizer's pipeline, anti-IL-4/ IL-13/ TSLP. Its studies are mostly in Dermatitis, Atopic · Asthma · Pulmonary Disease, Chronic Obstructive, led by Pfizer.

Furthest: phase 3, since Jan 22, 202611 company-led studies, 9 open or runningNext primary completion: Feb 20, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer119 open or runningphase 3since Jan 22, 2026Jun 6, 2022Feb 20, 2027phase 1 · NCT07792941
  • Named in Pfizer’s own pipeline as tilrekimig PF-07275315, phase 3, as of Nov 3, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 6, 2022First study: phase 1 study in Healthy VolunteersFirst studyNCT05411588 · 65 enrolled · United States, Belgium
  2. Jul 26, 2023Phase 2 study in Dermatitis, AtopicNCT05995964 · 507 enrolled · United States, Australia, Canada and more
  3. Nov 4, 2024Phase 1 study in HealthyNCT06675188 · 13 enrolled · China
  4. Apr 25, 2025Phase 2 study in AsthmaNCT06977581 · 252 planned · United States, Argentina, Belgium and more
  5. Jan 22, 2026Phase 3 study in Pulmonary Disease, Chronic ObstructivePhase 3 reachedNCT07363694 · 1,156 planned · United States, Argentina, Australia and more
  6. Aug 10, 20263 phase 3 studiesNCT07765888, NCT07772921, NCT07783425
  7. Aug 25, 2026Phase 1 study in HealthyNCT07792941 · 12 enrolled · United States
  8. Sep 18, 20262 phase 3 studiesNCT07839884, NCT07869043

Ahead

  1. Nov 12, 2026Primary completion: phase 2 study in Dermatitis, AtopicNCT05995964
  2. Feb 20, 2027Primary completion: phase 1 study in HealthyNCT07792941
  3. Mar 8, 2027Primary completion: phase 2 study in AsthmaNCT06977581
  4. Mar 10, 2028Primary completion: phase 3 study in Dermatitis, AtopicNCT07765888

TargetBeta

“anti-IL-4/ IL-13/ TSLP”the company's pipeline, read by Claude · source

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07869043Asthma · United States, Puerto Rico3RecruitingJun 7, 20291,100
NCT07839884Pulmonary Disease, Chronic Obstructive3Not yet recruitingMay 12, 20341,360
NCT07792941Healthy · United States1Active, not recruitingFeb 20, 202712
NCT07783425Dermatitis, Atopic · United States, Canada, Japan and more3RecruitingSep 8, 20281,375
NCT07772921Asthma · United States, Japan3RecruitingJun 1, 20291,100
NCT07765888Dermatitis, Atopic · United States, Canada, Japan3RecruitingMar 10, 2028375
NCT07363694Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more3RecruitingOct 24, 20301,156
NCT06977581Asthma · United States, Argentina, Belgium and more2RecruitingMar 8, 2027252
NCT06675188Healthy · China1CompletedJul 14, 202513
NCT05995964Dermatitis, Atopic · United States, Australia, Canada and more2Active, not recruitingNov 12, 2026507
NCT05411588Healthy Volunteers · United States, Belgium1CompletedMay 13, 202465

How it is read

Names in the registry

  • “PF-07275315”, 4 entries
  • “Tilrekimig”, 3 entries
  • “tilrekimig”, 2 entries
  • “PF-07275315 dose 1”, 1 entry
  • “PF-07275315-dose 2”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.